AI Consensus Investment Thesis
Lonza Group (LONN) Stock Forecast and AI Rating
Forecast targets and rating
Final recommendation
BUY
Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.
1-Year
BUY611 CHF
+11.9%+12.4% incl. dividends5-Year
BUY891 CHF
+63.4%+66.7% incl. dividendsLatest flagship insight
Western Biomanufacturing Dominance Unlocks Structural Multiyear Free Cash Flow Inflection
High consensus confirms that maturing mammalian capacity, geopolitical reshoring, and portfolio simplification are driving structural margin expansion. While persistent currency drag and early-stage biotech financing remain frictions, cresting capital expenditure unlocks substantial free cash flow, solidifying an indispensable transatlantic biopharmaceutical tollbooth.
This is the latest published deep-analysis batch. Audit published forecasts in full transparency
Warren Buffett (Value Purist), Machiavelli (Insider), Superintelligence (Anthropologist), Universal Investor (Polymath), Ray Dalio (Strategist), Sherlock Holmes (Whistleblower), Michael Burry (Vulture), J.P. Morgan (Titan), Elon Musk (Visionary). Some archetypes run in multiple modes, resulting in 14 advisors total.
Gemini
Claude
ChatGPTExecutive Summary
Dotted terms open concise definitions. Browse technical terms
If you invested $10,000 in Lonza Group at the forecast anchor (2026-09-18): $17,487 in five years versus $13,892 for S&P 500 benchmark.
* Return is calculated incl. 0.4% net dividend yield for Lonza Group.
20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView tableClose table
Frozen forecast from 18 Sept 2026. Prices in CHF; returns exclude dividends. Each quarter is compounded from the previous quarter.
Swipe the table horizontally to read every column.
| Quarter | Target (CHF) | Quarter return | Total return | Forecast rationale |
|---|---|---|---|---|
| Q4 2026 | 558.29 | +2.33% | +2.33% | Finalizing the consumer health divestment injects substantial upfront cash, eliminating short-term borrowing. Investors balance balance-sheet de-risking and pure-play portfolio clarity against pre-announced second-half maintenance phasing and persistent Swiss franc translational drag. |
| Q1 2027 | 575.12 | +3.01% | +5.41% | Full-year financial reporting confirms recurring operating margins within guided corridors, validating underlying manufacturing strength. Positive operating cash flow and initial third-party commercial contract announcements at Vacaville prompt constructive earnings revisions across healthcare equity desks. |
| Q2 2027 | 592.31 | +2.99% | +8.56% | Western biopharma clients accelerate commercial batch reservations under tightening supply-chain mandates. Commercial commissioning at Swiss drug-product sites adds visible capacity, offsetting lingering early-stage biotech venture funding softness with resilient commercial biologic volume. |
| Q3 2027 | 610.56 | +3.08% | +11.91% | Interim half-year results confirm accelerating operating cash conversion and steady mammalian utilization. Early client qualification milestones across transatlantic facilities reassure markets regarding technical integration timelines, driving measured valuation multiple recovery. |
| Q4 2027 | 626.83 | +2.67% | +14.89% | Multi-year commercial supply agreements for advanced antibody-drug conjugates expand contracted backlog into late decade. Favorable modality mix and capital expenditure discipline support solid quarterly operating performance heading into annual budget allocations. |
| Q1 2028 | 649.72 | +3.65% | +19.08% | Annual results demonstrate decisive free cash flow inflection as growth capital spending eases below historical thresholds. Management introduces expanded shareholder capital return initiatives, reinforcing investor confidence in normalized return on invested capital. |
| Q2 2028 | 662.83 | +2.02% | +21.49% | Vacaville transitions from legacy partner output into higher-margin commercial contracts, unlocking site operating leverage. High-barrier bioconjugate batch deliveries in Europe sustain solid gross margins despite persistent safe-haven currency translation penalties. |
| Q3 2028 | 681.66 | +2.84% | +24.94% | Mid-year reporting verifies stable underlying unit margins across mammalian suites, though competitive capacity announcements from rival contract manufacturers cap speculative multiple expansion. Fundamental performance remains anchored by non-discretionary blockbuster therapies. |
| Q4 2028 | 700.46 | +2.76% | +28.38% | Commercial scaling of integrated drug substance and sterile fill-finish operations broadens revenue capture per molecule. Contractual inflation pass-through clauses insulate operating income against utility and raw material cost fluctuations. |
| Q1 2029 | 721.38 | +2.99% | +32.22% | Financial reporting confirms sustained double-digit operating earnings growth and robust balance-sheet health. Organic cash generation comfortably funds selective specialized modality upgrades, cementing the franchise's standing among dependable European compounders. |
| Q2 2029 | 739.69 | +2.54% | +35.57% | Commercial launches of partnered oncology therapies drive high-capacity bioreactor scheduling. Incremental batch volumes generate operating leverage, supporting predictable quarterly appreciation even as overall European industrial equity momentum moderates. |
| Q3 2029 | 752.14 | +1.68% | +37.86% | Routine summer facility re-certifications and maintenance schedules produce standard seasonal volume consolidation. Pristine regulatory audit records and durable customer switching costs preserve firm contract pricing across all major campuses. |
| Q4 2029 | 771.37 | +2.56% | +41.38% | Specialized modalities capture commercial milestone payments as advanced cell and gene programs achieve clinical validation. Strong operational cash collection heading into fiscal year-end provides strategic flexibility for bolt-on capability investments. |
| Q1 2030 | 793.97 | +2.93% | +45.52% | Audited annual disclosures highlight free cash flow conversion exceeding half of operating profit, validating long-term capital reallocation. Progressive dividend expansion and steady equity repurchases continue to compound per-share intrinsic value. |
| Q2 2030 | 808.20 | +1.79% | +48.13% | Expanded automated bioprocessing suites achieve full run-rate throughput, enhancing batch yields and reducing labor intensity. Contract renewals with top-tier pharmaceutical sponsors incorporate multi-year take-or-pay volume protections. |
| Q3 2030 | 823.83 | +1.93% | +51.00% | Global healthcare procurement reviews maintain pricing discipline across mature biologics, but integrated antibody-drug conjugate complexity insulates overall corporate margins. Trading remains defensive and steady amidst shifting international macroeconomic conditions. |
| Q4 2030 | 840.42 | +2.01% | +54.04% | Commercial batch fulfillment finishes on schedule across European and North American facilities. High capacity utilization and negligible net debt support stable valuation multiples heading into annual portfolio rebalancing. |
| Q1 2031 | 861.00 | +2.45% | +57.81% | Full-year results confirm enduring mid-teens returns on capital, driven by mature mammalian assets and specialized synthesis platforms. Institutional capital continues accumulating the shares as a core defensive healthcare holding. |
| Q2 2031 | 875.21 | +1.65% | +60.41% | Capital expenditures stabilize at baseline maintenance levels, maximizing operational cash conversion. Incremental capacity additions operate under pre-contracted customer demand, generating predictable operating margins without speculative asset buildout. |
| Q3 2031 | 891.48 | +1.86% | +63.39% | The forecast horizon closes with the enterprise firmly positioned as an indispensable Western biomanufacturing infrastructure champion. Compounding commercial cash flows and durable regulatory moats secure a fully normalized, premium terminal valuation. |
The central economic thesis rests on an impending inflection in capital efficiencycapital efficiencyHow much value or profit is produced for each unit of invested capital.View full glossary entry and operating leverageoperating leverageThe sensitivity of operating profit to changes in revenue caused by the mix of fixed and variable costs.View full glossary entry as an intensive five-year asset buildout matures. Following the acquisition of Vacaville's 330,000-liter mammalian capacity and the divestment of commoditized capsule operations, the business emerges as an optimized pure-play biopharmaceutical CDMOcontract development and manufacturing organizationContract development and manufacturing organization (CDMO) refers to a firm that provides outsourced development, production, and related services for drug or biotech programs.View full glossary entry. Multi-year statutory accounting noise has obscured underlying operating income growth, while capital expenditurecapital expenditureCapital expenditure (CAPEX) is spending on long-lived assets or major improvements expected to support operations over multiple periods.View full glossary entry moderates from peak levels above 25% of revenue toward mid-teens. Commercial biologics outsourcing remains non-discretionary, insulated by prohibitive regulatory switching costsswitching costsFinancial, operational, technical, contractual, or learning costs incurred when changing products or providers.View full glossary entry and Western reshoringreshoringMoving production or supply operations back to the domestic market from overseas locations.View full glossary entry mandates that drive long-term capacity absorption. Valuation sensitivity centers on the duration of cash conversion under restrictive global monetary policy, where higher discount rates penalize delayed cash flows. Furthermore, persistent Swiss francswiss francThe Swiss franc (CHF) is the official currency of Switzerland and Liechtenstein.View full glossary entry real appreciation extracts ongoing translation drag against foreign-denominated customer contracts. Nevertheless, enterprise resilience is anchored by an unbreachable cGMP moat, premium pricing across complex antibody-drug conjugate synthesis, and significant balance-sheet deleveragingdeleveragingThe process of reducing total debt and leverage to strengthen financial stability.View full glossary entry.
Key insights
- Cresting growth capital expenditurescapital expenditureCapital expenditure (CAPEX) is spending on long-lived assets or major improvements expected to support operations over multiple periods.View full glossary entry release substantial operating cash flowoperating cash flowCash generated or consumed by a company's core business operations.View full glossary entry, converting accounting operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry into durable, self-funding shareholder distributions.
- Western legislative biosecurity mandates create captive commercial demand, permanently elevating large-scale mammalian capacity utilization across US and Swiss hubs.
- Structural customer lock-in via validated regulatory master files insulates commercial commercialization from early-stage venture biotech funding volatility.
This company acts like an essential tollbooth for the modern pharmaceutical industry. It produces complex, life-saving biologic medicines for major drug companies that lack their own specialized manufacturing plants. Having just completed a massive, multi-year construction spending spree and sold off its slower-growth consumer capsule division, the business is now set to generate substantial cash. While a strong Swiss currency and sluggish funding for early-stage biotech startups present minor hurdles, the overall business is remarkably protected because moving a medicine to a rival factory requires years of complex government approvals.
Key insights
- Completed factory expansions mean construction spending drops, allowing big operating profits to finally translate into real cash.
- Stricter international trade and security rules are forcing pharmaceutical companies to secure manufacturing inside North America and Europe.
- Long-term contracts for approved cancer blockbusters provide reliable, recession-resistant income that protects overall financial performance.
Deep Dive
Prevailing market consensus treats the equity as an expensive healthcare contractor whose recovery has stalled following guided second-half margin moderation and historical post-pandemic destocking. Media and sell-side commentary remain fixated on high trailing price-to-earnings ratios distorted by statutory write-downs, while assuming that higher global interest rates will permanently starve early-phase biotech clinical pipelines and cap multi-year operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry.
Paywalled preview begins: Deep Dive: detailed analysis
From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.
Deep Dive
Alpha Gap & Repricing Catalysts
Where does the current market narrative diverge from our AI Opinions—and what could close the gap?
Market Narrative
What does the market currently expect? Prevailing market consensus treats the equity as an expensive healthcare contractor whose recovery has stalled following guided second-half margin moderation and historical post-pandemic destocking. Media and sell-side commentary remain fixated on high trailing price-to-earnings ratios distorted by statutory write-downs, while assuming that higher global interest rates will permanently starve early-phase biotech clinical pipelines and cap multi-year operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The crowd materially underestimates value by confusing past peak capital expenditurescapital expenditureCapital expenditure (CAPEX) is spending on long-lived assets or major improvements expected to support operations over multiple periods.View full glossary entry and non-cash carve-out write-downs with operational deterioration. The market overlooks the dramatic structural shift underway: capital spending is tapering toward 16% of sales, while the consumer health divestment injects substantial cash to eliminate net debtnet debtTotal debt minus cash and cash equivalents.View full glossary entry. Crucially, consensus fails to model how captive onshoring demand under federal biosecurity policies will accelerate commercial mammalian utilization and expand normalized cash yields.
Repricing Catalyst
What could make the market recognize and close that gap? Formal closing of the consumer health divestment in late 2026 paired with the full-year 2026 earnings release provides the primary convergence catalyst. Demonstrating that core operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry hold above 33% alongside a decisive swing to positive free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry will dismantle market skepticism, forcing sell-side analysts to revise forward cash conversion models upward.
Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed / Fear
- Balanced
- Volatility
- Moderate
- Cycle position
- Growing Awareness
Sentiment aligns around steady operational execution, but diverges sharply between fears of biotech funding freezes and conviction in captive reshoringreshoringMoving production or supply operations back to the domestic market from overseas locations.View full glossary entry demand. This positioning tension dictates whether valuation re-rates immediately or paces gradual capacity validation.
Macro Regime Fit
Does the current market environment support the thesis? The prevailing macroeconomic setup presents a mixed backdrop that ultimately favors entrenched scale. Elevated central bank benchmark rates and tight liquidity constrain venture capital for speculative early-stage biotechs, creating demand friction in discovery pipelines. However, this is heavily countered by non-discretionary commercial medicine demand, contractual inflation escalators, and strategic sovereign biosecurity reshoringreshoringMoving production or supply operations back to the domestic market from overseas locations.View full glossary entry that insulates core biomanufacturing volumes.
Advisor Disagreement
What do our AI Advisors disagree about most? The decisive analytical debate centers on the speed and durability of free cash flow conversionfree cash flow conversionThe proportion of earnings, EBITDA, or another operating measure converted into free cash flow over a specified period.View full glossary entry. Bullish analyses argue that cresting capital expenditurescapital expenditureCapital expenditure (CAPEX) is spending on long-lived assets or major improvements expected to support operations over multiple periods.View full glossary entry, pure-play portfolio clarity, and captive onshoring demand will quickly lift core margins above 34% and unleash self-funding cash generation. Skeptical perspectives counter that Vacaville's complex technical transfers, prolonged biotech venture capital rationing, and safe-haven Swiss francswiss francThe Swiss franc (CHF) is the official currency of Switzerland and Liechtenstein.View full glossary entry strength will delay real cash realization until late decade. Furthermore, analysts dispute whether competitive capacity from Asian and European rivals commissioning post-2028 will erode long-term pricing powerpricing powerThe ability of a company to raise prices without losing significant customer demand.View full glossary entry. Tracking Vacaville contract onboarding and second-half free cash conversion will ultimately resolve this tension.
Base-Case Forces
Event Risk ScoreVery Low6/100Near-certain positive forces
Top Drivers / Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Biosecure Actbiosecure actBiosecure Act refers to legislation aimed at limiting reliance on certain biotechnology suppliers or data-linked firms for national security reasons.View full glossary entry Western Onshoring Mandate | Regulatory | +25% | +30% | Geopolitical decouplinggeopolitical decouplingA reduction in trade, investment, technology exchange, or supply-chain integration between countries or geopolitical blocs.View full glossary entry and Western biosecurity legislation compel multinational pharmaceutical innovators to systematically transfer commercial pipelines away from Chinese manufacturing contractors. Entrenched transatlantic cGMP facilities absorb displaced mammalian and conjugate programs, establishing long-term take-or-pay contracttake or pay contractsContracts requiring a buyer to pay for an agreed minimum quantity whether or not it is used.View full glossary entry backlogsbacklogThe total value of signed contracts yet to be fulfilled, representing future revenue visibility.View full glossary entry, strengthening commercial batch pricing powerpricing powerThe ability of a company to raise prices without losing significant customer demand.View full glossary entry, and expanding multi-year revenue visibilityrevenue visibilityHow clearly future revenue can be estimated from contracts, subscriptions, or recurring demand patterns.View full glossary entry across the horizon. |
| Vacaville Bioreactor Capacity Commercialization | Competitive Positioning | +22% | +26% | Acquiring Genentech's 330,000-liter Vacaville site secures massive mammalian capacity at roughly one-third of greenfield construction cost. Phasing out legacy partner production in favor of proprietary, higher-margin third-party commercial contracts drives significant fixed-cost leverage, structurally elevating operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry and compounding group operating income as site utilization crosses 80%. |
| Capital Expenditurecapital expenditureCapital expenditure (CAPEX) is spending on long-lived assets or major improvements expected to support operations over multiple periods.View full glossary entry Normalization Cash Harvest | Operational Efficiency | +18% | +21% | A multi-year investment supercycle that absorbed over 25% of annual sales is decisively cresting. As major mammalian, bioconjugation, and fill-finish complexes achieve regulatory commissioning, capital intensitycapital intensityA business condition where large upfront spending on assets and infrastructure is needed to operate and grow.View full glossary entry moderates toward mid-teens. This disciplined transition converts past heavy construction spend into substantial recurring free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry, supporting balance-sheet deleveragingdeleveragingThe process of reducing total debt and leverage to strengthen financial stability.View full glossary entry and shareholder distributions. |
| Antibody-Drug Conjugate Technological Moattechnological moatA durable competitive advantage created by proprietary technology, know-how, data, patents, engineering capability, or technical scale.View full glossary entry | Innovation And Product | +16% | +20% | The clinical expansion of complex antibody-drug conjugates requires difficult cytotoxic linker synthesis, antibody conjugation, and sterile drug product handling under strict regulatory containment. Rare end-to-end capabilities spanning payload synthesis to aseptic filling create severe supplier bottlenecks, enabling premium batch pricing, exceptional gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry, and expanding market share across next-generation oncology blockbusters. |
Near-certain negative forces
Top Frictions / Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Swiss Francswiss francThe Swiss franc (CHF) is the official currency of Switzerland and Liechtenstein.View full glossary entry Structural Currency Penalty | Macroeconomic And Macrofinancial | -12% | -14% | Persistent safe-haven demand drives ongoing real appreciation of the Swiss francswiss francThe Swiss franc (CHF) is the official currency of Switzerland and Liechtenstein.View full glossary entry against the US dollar and euro. Because over 80% of commercial revenue is invoiced abroad while significant technical overhead and corporate operations reside in Switzerland, foreign exchange translation friction continuously erodes nominal top-line growth and trims reported group earnings. |
| Prolonged High Rate Biotech Winter | Sector And Industry | -10% | -11% | Elevated central bank policy rates increase hurdle rates and restrict venture capital deployment into pre-revenue biotechnology innovators. Prolonged financing constraints lead emerging biopharma clients to defer exploratory pipelines and delay Phase I/II clinical trial reservations, creating persistent volume friction across early-development services and specialized therapeutic modality cleanrooms. |
| Vacaville Commercial Tech-Transfer Gestation | Operational Efficiency | -8.0% | -10% | Transitioning massive mammalian capacity from captive partner production to third-party commercial sponsors requires complex analytical comparability testing, pilot runs, and multi-quarter regulatory filings. This multi-year customer onboarding lag creates temporary facility overhead underabsorption, dampening near-term asset turnover and delaying peak return on invested capitalreturn on invested capitalReturn on invested capital (ROIC) measures how efficiently a business generates after-tax operating profit from the capital invested in its operations.View full glossary entry from newly integrated assets. |
| Bioprocessing Input Cost Inflationary Friction | Operational Efficiency | -6.0% | -8.0% | Geopolitical volatility and cleanroom energy demands keep regional utility overhead, specialized single-use bioprocess bags, and chromatography resins structurally expensive. Although master service agreements feature contractual inflation-indexing mechanisms, quarterly administrative pass-through lags expose operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry to temporary cost leakage during periods of volatile raw material and energy pricing spikes. |
What Could Break or Accelerate the Thesis
Plausible downside scenarios
Tail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Flagship Bioreactor Contamination Regulatory Halt | 18% | -28% | A severe microbial contamination, adventitious virus breach, or critical FDA Form 483 warning letter at a flagship mammalian hub like Vacaville or Visp would trigger mandatory production shutdowns. Remediating sterile cleanrooms, addressing client batch forfeitures, and managing regulatory audits would consume hundreds of millions in direct costs, stalling commercial releases and severely impairing institutional trust. |
| Big Pharma Modular In-Sourcing Wave | 21% | -22% | Major global pharmaceutical corporations could deploy surplus commercial cash flows to construct captive, automated internal manufacturing pods by 2028, reversing long-term outsourcing trends. Canceling third-party CDMOcontract development and manufacturing organizationContract development and manufacturing organization (CDMO) refers to a firm that provides outsourced development, production, and related services for drug or biotech programs.View full glossary entry capacity reservations upon contract expiration would strand large-scale bioreactor suites with unabsorbed fixed depreciation overhead, precipitating severe industry-wide price discounting and multi-year return compression. |
Plausible upside scenarios
Tail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Mandatory Federal BIOSECURE Supply Sanctions | 34% | +28% | Congress or executive agencies could eliminate transition safe harbors, mandating an immediate cut-off of federal biopharma procurement linked to designated foreign CDMOs by 2027. This regulatory trigger would spark a panicked scramble among global pharmaceutical sponsors for compliant Western commercial mammalian bioreactor capacity. Lonza would command premium capacity reservation fees, driving operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry beyond 36% and expanding annual free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry well above base-case projections. |
| Oncology ADC Commercial Mega-Blockbuster Surge | 26% | +24% | Simultaneous first-line regulatory approvals for multiple partnered antibody-drug conjugate candidates across major solid tumor indications between 2027 and 2029 could exhaust global bioconjugation capacity. Exclusive integrated supply agreements from payload synthesis to sterile fill-finish would maximize throughput across specialized suites, driving divisional operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry above 42% and catalyzing an aggressive equity re-rating. |
Company Financial Analysis
Lonza Group Earnings and Financials Analysis by AI
Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included.
Earnings and financials
AI Review
Headline financial results presented a confusing picture that masked robust underlying manufacturing health. In fiscal 2025, the company posted an optical statutory net loss of 275 million Swiss francs despite full-year sales jumping 19.2% to 6.53 billion francs. Forensic inspection confirms this paper loss stemmed from non-cash accounting write-downs taken to prepare the consumer capsules business for sale, rather than operational decay. Underlying contract manufacturing is gathering powerful momentum. Continuing operations accelerated into the first half of 2026, delivering 3.37 billion francs in revenue and a 38.7% surge in net profit to 591 million francs. As one-off separation noise fades, high-margin commercial biologics are establishing a strong, recurring earnings foundation.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | CHF 6.5B | CHF -275M | CHF -204M |
| 2024 | CHF 5.5B | CHF 636M | CHF -143M |
| 2023 | CHF 6.7B | CHF 654M | CHF -263M |
| 2022 | CHF 6.2B | CHF 1.2B | CHF -852M |
| 2021 | CHF 5.4B | CHF 2.9B | CHF -124M |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2025 | >100x | TTM | Native | CHF / CHF |
| 2024 | 30.8x | TTM | Native | CHF / CHF |
| 2023 | 12.2x | TTM | Native | CHF / CHF |
| 2022 | 27.7x | Annual | Native | CHF / CHF |
| 2021 | 19.3x | Annual | Native | CHF / CHF |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
AI Review
Profitability is experiencing structural expansion as customer demand shifts heavily toward high-complexity biologic medicines. Operating margins rebounded to 21.2% in 2025, while continuing operations achieved core margins of 34.8% during the first half of 2026. This operational strength reflects fixed-cost dilution across expanding production suites and commanding pricing power in specialized antibody-drug conjugates. While standard factory maintenance will produce normal second-half seasonal moderation, structural margins remain firmly elevated. Jettisoning lower-margin consumer capsule products and filling large-scale bioreactors with proprietary client therapies establishes a durable operating margin floor above 33% over the multi-year planning horizon.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2025 | CHF 1.4B | 21.2% | -4.2% |
| 2024 | CHF 1.1B | 19.9% | 11.6% |
| 2023 | CHF 854M | 12.7% | 9.7% |
| 2022 | CHF 1.3B | 21.7% | 19.5% |
| 2021 | CHF 819M | 15.1% | 54.4% |
Balance sheet and leverage
AI Review
The balance sheet reflects conservative financial stewardship engineered to withstand external macro volatility. The business closed 2025 with a prudent debt-to-equity ratio of 0.50 and strong interest coverage exceeding eight times operating income, confirming that borrowing remains well controlled despite the scale of recent acquisitions. Financial flexibility will expand dramatically upon the final closing of the consumer capsules divestment. Upfront cash proceeds will substantially eliminate net debt, providing ample dry powder to navigate elevated global interest rates, fund selective high-tech manufacturing upgrades, and return cash to shareholders through buybacks without financial strain.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Net cash / (debt) | Current ratio |
|---|---|---|---|---|
| 2025 | CHF 4.5B | CHF 719M | CHF 3.8B net debt | 2.21x |
| 2024 | CHF 5.1B | CHF 1.7B | CHF 4B net debt | 1.52x |
| 2023 | CHF 3.1B | CHF 1.7B | CHF 1.7B net debt | 1.77x |
| 2022 | CHF 2.6B | CHF 2.2B | CHF 1.2B net debt | 1.85x |
| 2021 | CHF 2.7B | CHF 3.2B | CHF 1.2B net debt | 2.50x |
Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
AI Review
Management has decisively concluded an aggressive five-year building boom that poured billions into stainless-steel bioreactors and cleanrooms. Between 2022 and 2024, capital spending absorbed between 21% and 26% of annual revenues, culminating in the 1.2 billion dollar purchase and modernization of the Vacaville site. This massive reinvestment deliberately restrained free cash flow to establish an unassailable manufacturing footprint ahead of global competitors. That intensive investment phase is now paying off. With major biologic suites fully qualified and capital intensity gliding toward mid-teens of sales, money previously consumed by construction will flow directly to the bottom line. This shift converts historical cash absorption into substantial, self-funding cash generation.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2025 | CHF 1.4B | CHF 112M |
| 2024 | CHF 1.4B | CHF 102M |
| 2023 | CHF 1.6B | CHF 105M |
| 2022 | CHF 1.9B | CHF 95M |
| 2021 | CHF 1.3B | CHF 90M |
Quarterly Forecast Scenarios
Lonza Group Averaged Consensus Scenarios
One row per forecast quarter. Asset scenario targets are shown in CHF; benchmark values are shown in USD.
Scroll to view all columns
| Quarter | Bear case (CHF) | Base case (CHF) | Bull case (CHF) | S&P 500 benchmark (USD) | FX (USD/CHF) |
|---|---|---|---|---|---|
| 529.23 CHF | 558.85 CHF | 567.42 CHF | $750.26 | 0.835018 | |
| 513.30 CHF | 576.16 CHF | 595.80 CHF | $736.44 | 0.842779 | |
| 528.70 CHF | 593.47 CHF | 613.67 CHF | $743.40 | 0.843422 | |
| 539.27 CHF | 611.79 CHF | 638.22 CHF | $755.15 | 0.84166 | |
| 539.27 CHF | 628.08 CHF | 657.36 CHF | $776.22 | 0.83753 | |
| 566.24 CHF | 650.93 CHF | 683.66 CHF | $787.13 | 0.830983 | |
| 588.89 CHF | 665.06 CHF | 704.17 CHF | $802.83 | 0.826943 | |
| 624.22 CHF | 683.23 CHF | 718.25 CHF | $812.05 | 0.82345 | |
| 642.95 CHF | 701.71 CHF | 739.80 CHF | $839.18 | 0.819449 | |
| 663.13 CHF | 722.88 CHF | 769.39 CHF | $850.50 | 0.813588 | |
| 683.03 CHF | 740.96 CHF | 792.32 CHF | $872.39 | 0.812505 | |
| 669.50 CHF | 753.92 CHF | 808.17 CHF | $885.51 | 0.808464 | |
| 696.28 CHF | 772.59 CHF | 832.41 CHF | $909.56 | 0.805183 | |
| 717.16 CHF | 795.25 CHF | 865.71 CHF | $916.13 | 0.801802 | |
| 726.76 CHF | 809.47 CHF | 883.03 CHF | $936.51 | 0.799593 | |
| 734.03 CHF | 825.14 CHF | 900.69 CHF | $947.34 | 0.795654 | |
| 748.71 CHF | 841.63 CHF | 918.70 CHF | $969.59 | 0.7930 | |
| 756.19 CHF | 862.21 CHF | 946.26 CHF | $979.99 | 0.790777 | |
| 763.76 CHF | 876.48 CHF | 965.19 CHF | $999.60 | 0.787519 | |
| 779.03 CHF | 892.60 CHF | 984.49 CHF | $1,012 | 0.78638 |
Behind the synthesis
How each opinion shapes the consensus
The synthesized research demonstrates strong independent convergence on core operational mechanics: the five-year capital expenditure supercycle has crested, the carve-out of commoditized capsule operations provides immediate balance-sheet deleveraging, and geopolitical mandates increasingly redirect commercial biologics toward audited Western infrastructure. However, material analytical disagreements emerge regarding the velocity of free cash flow conversion, the drag of Swiss franc translation, and duration sensitivity in an elevated interest rate regime. Uncritical extrapolations of reported margins into immediate distributable cash fail scrutiny due to multi-quarter qualification cycles at Vacaville and ongoing capital requirements for sterile fill-finish lines. Opinions providing rigorous semiannual reconstructions, verified regulatory timetables, and clear distinctions between statutory accounting write-downs and recurring manufacturing cash receive top weight. Conversely, perspectives assuming instantaneous multiple expansion or overlooking early-stage biotech funding headwinds are moderated, ensuring the consensus reflects industrial reality rather than speculative multiple inflation.
Universal Investor AI
The Polymath
GPT-6 AstraExemplary primary verification reconstructing continuing semiannual revenue and identifying trailing aggregation errors. Rigorously differentiates operational free cash flow from post-interest distributable cash, providing an unvarnished assessment of peer capacity additions and valuation constraints that justifies a leading allocation.
Universal Investor AI
The Polymath
Opus 5Provides exceptional independent evidence tracking statutory filings, legislative listings, and capital expenditure phasing. Discloses material valuation nuances, including duration sensitivity and rival capacity additions post-2028, balancing commercial mammalian scarcity against the delayed timing of cash conversion.
Universal Investor AI
The Polymath
Gemini 3.8 FlashAccurately details commercial biologics demand elasticity and regulatory onshoring dynamics. Grounded balance-sheet analysis properly contextualizes conservative gearing. However, assumptions regarding flawless Vacaville commercial absorption slightly underestimate multi-quarter regulatory filing timelines required for new client drug master files.
Sherlock Holmes AI
The Whistleblower
Gemini 3.8 FlashOffers meticulous forensic accounting disentangling non-cash carve-out write-downs from recurring CDMO operating profits. The analysis of second-half margin seasonality and capacity qualification timing is highly credible, balancing pure-play multiple expansion against ongoing Swiss franc foreign exchange drag.
Michael Burry AI
The Vulture
Gemini 3.8 FlashDelivers rigorous scrutiny of the gap between operational and distributable free cash flow, grounded in asset replacement values. Identifies legitimate risks regarding customer concentration in blockbuster therapies, though its terminal earnings growth assumptions lean somewhat conservative against verified biologics backlog expansion.
Ray Dalio AI
The Strategist
Gemini 3.8 FlashEstablishes a robust through-cycle macroeconomic view, linking capital expenditure supercycle maturation to sovereign supply-chain reordering. Effectively balances long-term take-or-pay contract stability against early-phase venture funding headwinds, delivering a well-evidenced framework for normalized returns on capital.
Superintelligence AI
The Anthropologist
Gemini 3.8 FlashProvides a disciplined counter-perspective emphasizing capital inertia, elevated trailing multiples, and multi-year depreciation friction. The evaluation accurately highlights delayed free cash flow realization, though it slightly understates the near-term margin support delivered by high-margin antibody-drug conjugate customer pipelines.
Warren Buffett AI
The Value Seeker
Gemini 3.8 FlashConstructs a compelling thesis on non-discretionary commercial medicine demand and high regulatory switching costs. While effectively identifying core operational resilience beneath temporary impairments, the projected multiple re-expansion is somewhat optimistic given prevailing high-rate sovereign yield pressures across European healthcare.
Niccolo Machiavelli AI
The Insider
Gemini 3.8 FlashThoroughly investigates geopolitical supply reallocation under federal biosecurity policies and transatlantic capacity dynamics. It captures the strategic moat of large-scale mammalian assets, though its assumption of rapid pricing power acceleration is slightly tempered by competitive Western capacity commissioning late-decade.
Universal Investor AI
The Polymath
Gemini 3.8 FlashSkillfully reconciles post-earnings trading pullbacks with underlying capital expenditure normalization and portfolio reshaping. The assessment of Vacaville transition gestation lags is economically sound, maintaining prudent expectations for mid-term free cash flow recovery despite wider biotech funding constraints.
Warren Buffett AI
The Value Seeker
Gemini 3.8 FlashIdentifies durable economic moats rooted in regulatory compliance and technical complexity across bioconjugates. The evaluation cleanly separates statutory portfolio write-downs from recurring CDMO earning power, though the timeline for third-party commercial batch onboarding at Vacaville is slightly ambitious.
Elon Musk AI
The Visionary
Gemini 3.8 FlashPresents strong insight into bioreactor titer advancements cannibalizing legacy steel capacity. However, aggressive multiples and rapid deleveraging assumptions overlook contractual transition lags and the reality that customers require lengthy comparability protocols before shifting volume away from established mammalian infrastructure.
Superintelligence AI
The Anthropologist
Gemini 3.8 FlashArticulates structural tailwinds from geopolitical supply-chain reorientation and portfolio simplification. While correctly identifying operational leverage in bioconjugates, its trajectory underweights the persistent translational currency friction of a strong Swiss franc against primary dollar and euro billing streams.
J.P. Morgan AI
The Titan
Gemini 3.8 FlashPresents a compelling perspective on Western manufacturing infrastructure consolidation and commercial biologics pricing power. However, projecting enterprise multiples past twenty times EBITDA discounts sovereign rate realities and understates early-stage biotech pipeline deferrals in specialized modalities.
Research Provenance
References & Context
This Lonza Group consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
- Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.
Independent AI Advisor panel
- AI Advisors
- 14
- AI Researchers
- 11
- AI Thinkers
- 3
Sources retained from AI Researcher searches
Asset-specific · Researcher webShowing the top 15 of 154 deduplicated sources retained for this batch.
- 01Federal Reserve Board - Federal Reserve issues FOMC statementfederalreserve.gov
- 02Relay Therapeutics, Inc. - Form 10-Q - FY2026sec.gov
- 03Lonza Completes its Transformation to a Pure-Play CDMO with Agreement to Divest...lonza.com
- 04Dividende LONZA GRP LONN, résultats et prévisions LONZA GRP, Cotation Bourse Swiss EBS Stocks - Boursoramaboursorama.com
- 05Lonza Divests Capsules & Health Ingredients Business for $3 Billion • CHEManager is the market-leading medium for the management of the chemical and pharmaceutical industrychemanager-online.com
- 06U.S. Pharma Tariffs And MFN Become Law After April 2 Updateclinicalleader.com
- 07Trump Administration Imposes Section 232 Tariffs on Patented Pharmaceutical Imports; Tiered Rate Structure Takes Effect Beginning July 31, 2026 | Crowell & Moring LLPcrowell.com
- 08Earnings call transcript: Lonza H1 2026 profit gains fail to lift shares By Investing.cominvesting.com
- 09Lonza Group (LONN) Stock Forecast & Price Target - Investing.cominvesting.com
- 10Lonza H1 2026 slides: margin upgrade overshadowed by muted outlook By Investing.cominvesting.com
- 11Linklaters advises Lonza on divestment of its Capsules & Health Ingredients (CHI) businesslinklaters.com
- 12Lonza lifts margin target, repeats latter half of 2026 to be slower | livelive.euronext.com
- 13https://www.lonza.com//-/media/Lonza/Lonzacom/investor-relations/Financial%20Presentations/2026_half-year_presentationlonza.com
- 14https://www.lonza.com//-/media/Lonza/Lonzacom/investor-relations/Financial%20Reports/2026_half-year_APM_reportlonza.com
- 15https://www.lonza.com//-/media/Lonza/Lonzacom/investor-relations/Financial%20Reports/2026_half-year_reportlonza.com
And 139 more sources were used and retained in the batch inventory.
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market and World-Events Context Through September 20
Download Archived SnapshotCoverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20
January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.
Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| Renewed monetary tightening amid persistent inflation | 2026-01-30 | ACTIVE POLICY REGIME |
| Iran/Hormuz conflict and wider energy-security disruption | 2026-02-28 | ONGOING |
| Tariff legal reset and strategic supply restrictions | 2026-02-20 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental context
Income statement
9 fieldsdepreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields
Balance sheet
12 fieldscash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields
Cash flow
5 fieldscapitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field
annual: 2014-12-31–2025-12-31, 12 periods; quarterly: 2023-12-31–2026-06-30, 6 periods
Currencies cited: CHF, USD (quote CHF; primary reporting CHF; converted/valuation USD).
End of the paywalled preview
The excerpt from Deep Dive: detailed analysis to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.
Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.
Additional with full access
Individual AI Advisor reports
- Investment theses
- Bull and bear scenarios and alpha signals
- Drivers, headwinds, risks and opportunities
- Quarterly forecast rationale
- Advisor research references and configuration
Additional datasets and interactive tools
- Interactive forecast comparisons
- Available detailed financial statements
- Market history and corporate-action adjustments
- Eligible historical publication workspaces
Explore complete public research examples
These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.